Wolfgang Siess
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases-Executive Summary.
Journal: Thrombosis and haemostasis
Published: July 08, 2026
Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.
Journal: Circulation
Published: February 09, 2026
Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase.
Journal: International journal of molecular sciences
Published: December 03, 2021
VITT after ChAdOx1 nCoV-19 Vaccination.
Journal: The New England journal of medicine
Published: November 03, 2021
Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time.
Journal: Frontiers in cardiovascular medicine
Published: July 28, 2021
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
Journal: Thrombosis and haemostasis
Published: April 13, 2021
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Journal: Cancers
Published: February 11, 2021
Targeting platelet-derived CXCL12 impedes arterial thrombosis.
Journal: Blood
Published: November 25, 2020
Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.
Journal: Platelets
Published: September 07, 2020
Glycoprotein VI is not a Functional Platelet Receptor for Fibrin Formed in Plasma or Blood.
Journal: Thrombosis and haemostasis
Published: June 04, 2020
Last Updated: 09/26/2026